How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,098 results for

Defensive Medicine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

4901. Malignant Pleural Effusion With ZD6474

the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00402896 Locations Layout table for location information United States, Texas UT MD Anderson Cancer Center Houston, Texas, United States, 77030 Sponsors and Collaborators M.D. Anderson Cancer Center United States Department of Defense AstraZeneca (...) of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00402896 Recruitment Status : Terminated (Slow Accrual) First Posted : November 22, 2006 Results First Posted : March 9, 2016 Last Update Posted : March 9, 2016 Sponsor: M.D. Anderson Cancer Center Collaborators: United States Department of Defense AstraZeneca Information provided

2006 Clinical Trials

4902. Spousal Relationships and Pain in Metastatic Breast Cancer

in Metastatic Breast Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00386620 Recruitment Status : Completed First Posted : October 11, 2006 Last Update Posted : July 7, 2015 Sponsor: M.D. Anderson Cancer Center Collaborator: United States Department of Defense Information provided by (Responsible (...) : 548 participants Observational Model: Cohort Time Perspective: Prospective Official Title: Spousal Relationships and Pain in Metastatic Breast Cancer Study Start Date : October 2004 Actual Primary Completion Date : July 2015 Resource links provided by the National Library of Medicine related topics: related topics: Groups and Cohorts Go to Group/Cohort Intervention/treatment Survey + ED Part 1: Survey + Electronic Diaries (ED) Part 2: 3 Month, 6 Month Survey + ED Behavioral: Questionnaire 45

2006 Clinical Trials

4903. A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease

Collaborators: United States Department of Defense Molecular NeuroImaging Information provided by (Responsible Party): Institute for Neurodegenerative Disorders Study Details Study Description Go to Brief Summary: This study is designed as a prospective cohort study to test the strategy of combining two biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug, [123I]β-CIT , in a population of first-degree relatives of PD patients as a tool to establish an 'at risk' Parkinson (...) Completion Date : August 2020 Resource links provided by the National Library of Medicine related topics: related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: [123I]β-CIT and SPECT imaging To Assess [123I]β-CIT and SPECT imaging Procedure: [123I]β-CIT and SPECT imaging This study is designed as a prospective cohort study to test the strategy of combining two biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug, [123I]β-CIT

2006 Clinical Trials

4904. Investigation Into the Effects Upon Brain Response to Change in Cirucating Glose Levels in Diabetes Mellitus

is central to the recognition of hypoglycemia and the coordination of the counterregulatory response. Neural tissue depends mainly on glucose for its energy supply. As circulating glucose falls beneath the level needed to maintain glucose transport across the blood-brain barrier, a variety of defense mechanisms are activated, including symptoms of cognitive dysfunction. However, the precise nature and causes of the adverse CNS effects of hypoglycemia are not well understood. Functional magnetic resonance (...) Start Date : August 2001 Estimated Primary Completion Date : August 2020 Estimated Study Completion Date : August 2020 Resource links provided by the National Library of Medicine related topics: related topics: Groups and Cohorts Go to Group/Cohort conventionally treated conventionally treated, relatively poorly controlled patients with type 1 diabetes intensively treated intensively treated, well controlled patients with type 1 diabetes lean healthy age- and sex- matched non-diabetic, normal weight

2007 Clinical Trials

4905. Relation of White Blood Cell Function to Diabetes

will evaluate study subjects' glucose tolerance and insulin sensitivity and draw blood to examine peripheral monocytes. Biological readouts will include: 1) the quantification of the mitochondrial genomic and electron transfer chain content; 2) the determination of mitochondrial reactive oxygen species capacity and defenses; 3) the pattern of monocyte differentiation and 4) the unbiased assessment of monocyte gene expression and proteome. If the mitochondrial hypothesis is operational, this study will show (...) and Diabetic Subjects Study Start Date : November 27, 2007 Actual Primary Completion Date : October 19, 2009 Groups and Cohorts Go to Outcome Measures Go to Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below

2007 Clinical Trials

4906. An Evaluation of the SOS (Suicide Prevention) Program

Department of Defense Information provided by (Responsible Party): ROBERT H. ASELTINE, UConn Health Study Details Study Description Go to Brief Summary: The purpose of this study was to investigate the impact of the SOS suicide prevention program on help-seeking, attitudes toward depression and suicide, and suicidal behavior among high school students. Current research protocol has extended this evaluation to the Middle School version of SOS. Condition or disease Intervention/treatment Phase Suicide (...) Completion Date : December 2012 Actual Study Completion Date : June 2014 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: 1 receive SOS program Behavioral: SOS program screening and didactic programming to raise awareness of depression suicidality Other Name: Signs of Suicide Outcome Measures Go to Primary Outcome Measures : suicide attempts [ Time Frame: 3 months ] Secondary Outcome Measures : knowledge

2006 Clinical Trials

4907. Adapting Tools to Implement Stroke Risk Management to Veterans

for these events. Second, the Veteran Stroke Prevention Program takes into account the varied resources and services offered in VAMCs across the nation, allowing the program to be tailored both to a given facility and to the individual veteran's needs and readiness to change. Importantly, the program could allow all VA facilities to offer guideline-concurrent stroke risk reduction programs and therefore increase compliance with VA/Department of Defense, American Heart Association, and the Joint Commission (...) of hypertension drugs (range = 0-100%) Compliance is defined as Medication Possession Ratio for Hypertension drugs dichotomized as greater than and equal to 80%. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below

2006 Clinical Trials

4908. BATTLE Program: Tarceva and Targretin in Patients With NSCLC

Collaborator: United States Department of Defense Information provided by (Responsible Party): M.D. Anderson Cancer Center Study Details Study Description Go to Brief Summary: The goal of this clinical research study is to evaluate the effectiveness of Tarceva® (OSI-774, erlotinib hydrochloride) in combination with Targretin® (bexarotene) in treating NSCLC. The safety of this treatment will also be studied, as well as the treatment's effect on different cells in the body and the participants' overall (...) Cancer (NSCLC) Actual Study Start Date : November 29, 2006 Actual Primary Completion Date : February 23, 2018 Actual Study Completion Date : February 23, 2018 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Bexarotene + Erlotinib Bexarotene 400 mg/m^2 by mouth daily x 28 Days. Erlotinib 150 mg by mouth daily x 28 Days. Drug: Bexarotene 400 mg/m^2 by mouth daily x 28 Days

2006 Clinical Trials

4909. BATTLE Program: Sorafenib in Patients With NSCLC

and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00411671 Recruitment Status : Completed First Posted : December 14, 2006 Results First Posted : February 11, 2016 Last Update Posted : February 11, 2016 Sponsor: M.D. Anderson Cancer Center Collaborators: United States Department of Defense Bayer Information provided (...) participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Phase II Study of Sorafenib (BAY 43-9006) in Chemorefractory Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Study Start Date : November 2006 Actual Primary Completion Date : November 2012 Actual Study Completion Date : November 2012 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go

2006 Clinical Trials

4910. Increased Calorie Intake to Reverse Energy Deficiency in Exercising Women: Impact on Bone and Menstrual Cyclicity

Last Update Posted : May 8, 2017 Sponsor: Penn State University Collaborator: United States Department of Defense Information provided by (Responsible Party): Mary Jane DeSouza, Penn State University Study Details Study Description Go to Brief Summary: The purpose of this study is to examine the effects of increased food intake on the menstrual cycle and bone health in physically active women who have irregular or absent menstrual cycles. This study will examine whether a 12 month period (...) : September 2006 Actual Primary Completion Date : December 2014 Actual Study Completion Date : December 2014 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: EAMD+Calories This group contains women with exercise-associated menstrual disturbances (EAMD) and receives an intervention of increased caloric intake during the 12-month intervention. The targeted increase in caloric intake is 20-30% of baseline energy

2006 Clinical Trials

4911. Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease

sperm tail function or structure. Patients suspected of having a variant of CF or PHA, including nontuberculous mycobacterial lung disease, have the following additional procedures: Sweat chloride test: A medicine is placed on the arm to produce sweat; then, a very low level of electric current is applied for 5 to 12 minutes. Sweat is collected in a plastic tube and tested for salt content. Blood draw for CF genetic testing, if necessary, and to measure levels of the enzyme trypsin. Saliva (...) ciliary dyskinesia (PCD), variant cystic fibrosis (CF), and pseudohypoaldosteronism (PHA). These studies are also applicable to diseases where altered airways clearance may play a primary or contributory role such as nontuberculous mycobacterial lung disease, chronic granulomatous disease, and the hyper-IgE syndromes. Disorders such as PCD, CF, and PHA reflect genetic defects in airway host-defense, and typically result in chronic infection of the airways. Patients with these disorders

2006 Clinical Trials

4912. Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel

throughout the world. Development of vaccines has been difficult because shigellae are habitants of and pathogens for humans only and there is no consensus about the mechanism(s) of immunity to this pathogen. Incomplete, but compelling evidence, indicates that a critical level of serum IgG anti-LPS confers immunity to shigellosis. Important data come from our clinical trial in the Israel Defense Forces (IDF) recruits. A randomized, double-blind, vaccine-controlled study showed that the S. sonnei-rEPA (...) to this pathogen. Incomplete, but compelling evidence, indicates that a critical level of serum IgG anti-LPS confers immunity to shigellosis. A randomized, double-blind, vaccine-controlled study in Israel Defense Force (IDF) recruits showed that the S. sonnei-rEPA elicited 74% protection against shigellosis occurring about 3 months after vaccination (p=0.001). This vaccine also conferred 43% (p=0.04) protection in one company during an outbreak up to 17 days following vaccination suggesting that our Shigella

2006 Clinical Trials

4913. Enteroaggregative E.Coli (EAEC)

Description Go to Brief Summary: Enteroaggregative E. coli (EAEC) is a bacterium that can cause diarrhea. The purposes of this study are to: determine how much EAEC is needed to cause diarrhea in a healthy person, determine if a genetic factor is important in causing diarrhea, and to see how the body's defenses control EAEC. Participants include 25 healthy adults, ages 18-40. Volunteers will be assigned to 1 of 4 dose levels in groups of 5 volunteers each. One volunteer in each group will receive a sodium (...) in Adult Volunteers; Dose-Escalation Study Study Start Date : February 2008 Actual Primary Completion Date : August 2008 Actual Study Completion Date : December 2008 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: 1 Dosage 1X10^9 given orally in a sodium bicarbonate solution Drug: Levofloxacin Administered at a dose of 500 mg once a day for 3 days Drug: Placebo Sodium bicarbonate solution

2006 Clinical Trials

4914. Th1/Th2 Polarization and Linkage to L. Viannia Infection Outcomes

) Information provided by: Yale University Study Details Study Description Go to Brief Summary: The purpose of this study is to determine what types of cells participate in the defense of humans against Leishmania (skin parasites). People 18-70 years of age who have leishmaniasis, have healed leishmanial lesions, or are healthy are being invited to participate in this study. Approximately 150 people will participate in the study. Participants will be asked to provide some general information about (...) ) Infection Aim 1: To Determine if Th1/Th2 Polarization Occurs and is Linked to the Outcome of Infection by L. Viannia Study Start Date : December 2006 Actual Study Completion Date : April 2010 Resource links provided by the National Library of Medicine related topics: resources: Groups and Cohorts Go to Outcome Measures Go to Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family

2006 Clinical Trials

4915. Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer

Government. Read our for details. ClinicalTrials.gov Identifier: NCT00399529 Recruitment Status : Completed First Posted : November 15, 2006 Last Update Posted : December 13, 2012 Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Collaborators: American Cancer Society, Inc. Avon Foundation Cancer Treatment Research Foundation The Commonwealth Fund United States Department of Defense Genentech, Inc. Information provided by (Responsible Party): Sidney Kimmel Comprehensive Cancer Center (...) of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Allo GM-CSF-secreting vaccine, Trastuzumab, Cyclophosphamide Allogeneic GM-CSF-secreting breast cancer vaccine : the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 10^8 cells for each patient and each vaccination cycle) given intradermally every 4-6 weeks for 3 cycles

2006 Clinical Trials

4916. Pilot Study to Assess the Efficacy of Botulinum Toxin B on Pain and Disability in Subjects With Acute Low Back Pain

candidates in 2 years of recruiting) First Posted : October 6, 2006 Last Update Posted : March 2, 2010 Sponsor: United States Department of Defense Information provided by: Walter Reed Army Medical Center Study Details Study Description Go to Brief Summary: This study will test the hypothesis that Botulinum toxin B (Myobloc®) treatment reduces pain and disability in subjects suffering from acute low back pain due to an identifiable muscle strain or back trauma occurring 3 to 6 weeks prior to enrollment (...) in Subjects Suffering From Acute Low Back Pain Study Start Date : February 2008 Estimated Primary Completion Date : August 2010 Estimated Study Completion Date : August 2010 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: 1 Botulinum Toxin B Drug: Botulinum toxin B Botulinum Toxin B Other Name: Myobloc Placebo Comparator: 2 Placebo Drug: Placebo Placebo Outcome Measures Go to Primary Outcome

2006 Clinical Trials

4917. Pilot Study to Assess the Efficacy of Botulinum Toxin A Treatments on Pain and Disability in Sub-Acute Low Back Pain

to be secured for this study) First Posted : October 6, 2006 Last Update Posted : March 5, 2009 Sponsor: United States Department of Defense Information provided by: Walter Reed Army Medical Center Study Details Study Description Go to Brief Summary: This study will test the hypothesis that Botulinum toxin A (BOTOX®) treatment reduces pain and disability in subjects suffering from sub-acute low back pain due to an identifiable muscle strain or back trauma occurring 6 to 16 weeks prior to enrollment (...) : September 2011 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: 1 Botulinum Toxin A Drug: Botulinum Toxin A Botulinum Toxin A Other Name: Botox Placebo Comparator: 2 Placebo Drug: Placebo Placebo Outcome Measures Go to Primary Outcome Measures : Significant reduction of low back pain [ Time Frame: 8 weeks ] Secondary Outcome Measures : Significant reduction in long term disability [ Time Frame

2006 Clinical Trials

4918. Treatment of Refractory Schizophrenia With Riluzole

(amyotrophic lateral sclerosis, Lou Gehrig's disease) which is one of the most severe and rapidly progressing neurodegenerative illnesses that affects motor neurons in the brain and spinal cord. A subset of ALS is inherited and involves more than 70 different mutations in the antioxidant enzyme superoxide dismutase (SOD) thereby contributing to reduced antioxidative defense against oxidative injury. This results in increased reactive oxygen species level in several organs/tissues while the bulk (...) : Parallel Assignment Masking: Double (Participant, Care Provider) Primary Purpose: Treatment Official Title: Neuroprotective Treatment of Refractory Schizophrenia With Riluzole 01T-432 Study Start Date : May 2002 Estimated Primary Completion Date : May 2018 Estimated Study Completion Date : September 2018 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Riluzole Drug: Riluzole

2006 Clinical Trials

4919. VISN Collaborative for Improving Hypertension Management With ATHENA-HTN

participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Health Services Research Official Title: VISN Collaborative for Improving Hypertension Management With ATHENA-HTN Study Start Date : January 2007 Actual Primary Completion Date : May 2010 Actual Study Completion Date : March 2011 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: ATHENA-CDS-HTN (...) plus Guideline Link ATHENA-CDS-HTN plus Guideline Link. ATHENA-CDS-HTN display on the cover sheet of electronic health record, plus link to the guidelines Other: ATHENA-CDS-HTN plus Guideline Link ATHENA display provides guideline-based recommendations to clinicians at the time of patient care. Guideline Link Only Guideline Link Only. Link to The Seventh Report of the Joint National Committee on Prevention Detection and Treatment of High Blood Pressure (JNC7) and to VA-Department of Defense (DoD

2006 Clinical Trials

4920. Pulmonary dendritic cells. (PubMed)

Pulmonary dendritic cells. Dendritic cells (DCs) are leukocytes that are emerging as chief orchestrators of immune responses. The crucial task of DCs is the continuous surveillance of antigen-exposed sites throughout the body, and their unique responsibility is to decide whether to present sampled antigen in an immunogenic or tolerogenic way. Any misstep can either lead to a flawed immune defense or to allergy, even autoimmunity. It comes as no surprise that the lungs become increasingly (...) is a big challenge. This article aims to provide researchers and clinicians with an up-to-date view on DC biology and its relevance to pulmonary medicine. A developing trend in the field of DCs is the shift from fundamental immunologic research toward exciting clinical insights and applications. For the pulmonary clinician, this heralds the dawn of promising therapies in various domains such as infections, allergy, and cancer.

2005 American Journal of Respiratory and Critical Care Medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>